Benitec Biopharma Inc., a clinical-stage biotechnology company specializing in gene therapy, reported its financial results for the third fiscal quarter ending March 31, 2025. The company reported total expenses of $10.2 million for the quarter, a significant increase from $4.1 million in the same quarter of 2024. The net loss attributable to shareholders was $9.4 million, compared to a net loss of $4.3 million in the previous year's corresponding quarter. Benitec's research and development expenses, mainly associated with the clinical development of BB-301 for OPMD treatment, rose to $6 million from $2.6 million in the comparable quarter of 2024. The company's general and administrative expenses increased to $4.2 million from $1.6 million in the same period last year. As of March 31, 2025, Benitec held $103.6 million in cash and cash equivalents. The company is progressing with its clinical trials, having safely treated the final subject of Cohort 1 with a low dose of BB-301 in April 2025, and plans to enroll additional subjects at a higher dose later in the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.